The Safety and Efficacy of Escitalopram in Pediatric Patients With Major Depressive Disorder - Study Results

Study Type:	Interventional
Study Design:	Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment
Condition:	Major Depressive Disorder
Interventions:	Drug: Escitalopram Drug: Placebo

Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Recruitment period was from April 1, 2005 through March, 2007 at 40 centers in the US.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
2 week screening with one-week single-blind placebo. Patients meeting selection criteria at baseline were randomized to once daily escitalopram 10-20mg/day or placebo (1:1).

Reporting Groups

	Description
Escitalopram	Once daily oral administration of escitalopram tablets - 1 tablet (10mg) for the first three weeks, then 1 tablet (10mg or 20mg) depending on therapeutic response and tolerability.
Placebo	Once daily oral administration of placebo tablets

Participant Flow: Overall Study

	Escitalopram	Placebo
STARTED	155^[1]	157^[2]
COMPLETED	126	133
NOT COMPLETED	29	24
Adverse Event	4	1
Lack of Efficacy	5	5
Protocol Violation	3	0
Withdrawal by Subject	8	9
Lost to Follow-up	8	6
Pregnancy	0	1
moving away from site	1	1
death of parent	0	1

[1]	Safety Population defined as all patients who took at least one dose of double-blind study drug
[2]	Safety Population defined as all patients who took at least one dose of double-blind study drug

Baseline Characteristics

Hide Baseline Characteristics

Reporting Groups

	Description
Escitalopram	Once daily oral administration of escitalopram tablets - 1 tablet (10mg) for the first three weeks, then 1 tablet (10mg or 20mg) depending on therapeutic response and tolerability.
Placebo	Once daily oral administration of placebo tablets

Baseline Measures

	Escitalopram	Placebo	Total
Number of Participants [units: participants]	155	157	312
Age [units: participants]
<=18 years	155	157	312
Between 18 and 65 years	0	0	0
>=65 years	0	0	0
Age [units: years] Mean ± Standard Deviation	14.7 ± 1.6	14.5 ± 1.5	14.6 ± 1.6
Gender [units: participants]
Female	92	92	184
Male	63	65	128
Region of Enrollment [units: participants]
United States	155	157	312

Outcome Measures

Show All Outcome Measures

1. Primary:

Change in Children's Depression Rating Scale - Revised (CDRS-R) Total Score [ Baseline to end of week 8 ]

Show Outcome Measure 1

2. Secondary:

Clinical Global Impressions - Improvement [ At end of weeks 1-8 ]

Show Outcome Measure 2

3. Other Pre-specified:

Children's Global Assessment Scale [ At baseline and end of week 8 ]

Show Outcome Measure 3

Serious Adverse Events

Show Serious Adverse Events

Other Adverse Events

Hide Other Adverse Events

Time Frame	No text entered.
Additional Description	No text entered.

Frequency Threshold

Threshold above which other adverse events are reported	5%

Reporting Groups

	Description
Escitalopram	Once daily oral administration of escitalopram tablets - 1 tablet (10mg) for the first three weeks, then 1 tablet (10mg or 20mg) depending on therapeutic response and tolerability.
Placebo	Once daily oral administration of placebo tablets

Other Adverse Events

	Escitalopram	Placebo
Total, other (not including serious) adverse events
# participants affected / at risk	121	118
Gastrointestinal disorders
Nausea * ^A # participants affected / at risk	16/155 (10.32%)	13/157 (8.28%)
Abdominal Pain * ^A # participants affected / at risk	14/155 (9.03%)	11/157 (7.01%)
Vomiting * ^A # participants affected / at risk	10/155 (6.45%)	9/157 (5.73%)
Diarrhoea * ^A # participants affected / at risk	8/155 (5.16%)	5/157 (3.18%)
General disorders
Inflicted Injury * ^A # participants affected / at risk	14/155 (9.03%)	21/157 (13.38%)
Fatigue * ^A # participants affected / at risk	12/155 (7.74%)	13/157 (8.28%)
Influenza-like Symptoms * ^A # participants affected / at risk	11/155 (7.10%)	5/157 (3.18%)
Nervous system disorders
Headache * ^A # participants affected / at risk	39/155 (25.16%)	40/157 (25.48%)
Psychiatric disorders
Insomnia * ^A # participants affected / at risk	16/155 (10.32%)	10/157 (6.37%)
Reproductive system and breast disorders
Menstrual Cramps * ^A # participants affected / at risk	10/155 (6.45%)	14/157 (8.92%)
Respiratory, thoracic and mediastinal disorders
Pharyngitis * ^A # participants affected / at risk	13/155 (8.39%)	15/157 (9.55%)
Rhinitis * ^A # participants affected / at risk	11/155 (7.10%)	14/157 (8.92%)
Upper Respiratory Tract Infections * ^A # participants affected / at risk	8/155 (5.16%)	12/157 (7.64%)

*	Indicates events were collected by non-systematic assessment.
^A	Term from vocabulary, WHOART v.1998/04

More Information

Hide More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

The agreement is:

	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. Restriction Description: Sponsor can review results communications prior to public release & can embargo communications re: results for 90 days from time submitted to sponsor for review. PI shall not disclose sponsor’s confidential info. Upon sponsor’s request, PI shall delete any proprietary info & shall not include raw data in pub. On sponsor’s request, PI shall delay submission for any pub while sponsor files patent apps. If trial is multi-center, PI agrees that first publication shall be a multi-center pub.

Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

Results Point of Contact:

Name/Title: Daniel Ventura, PhD
Organization: Forest Research Institute, a subsidiary of Forest Laboratories, Inc.
phone: 201-427-8252
e-mail: daniel.ventura@frx.com

No publications provided by Forest Laboratories

Publications automatically indexed to this study:

Emslie GJ, Ventura D, Korotzer A, Tourkodimitris S. Escitalopram in the treatment of adolescent depression: a randomized placebo-controlled multisite trial. J Am Acad Child Adolesc Psychiatry. 2009 Jul;48(7):721-9.

Responsible Party:	Forest Research Institute, a subsidiary of Forest Laboratories, Inc. ( Anjana Bose, PhD )
Study ID Numbers:	SCT-MD-32
Study First Received:	April 5, 2005
Results First Received:	April 21, 2009
Last Updated:	September 25, 2009
ClinicalTrials.gov Identifier:	NCT00107120 History of Changes
Health Authority:	United States: Food and Drug Administration